SIStockInvestingSI.com

NYSE · MCK · Medical Distribution

McKesson (MCK) stock analysis

$1015.50−1.42%Data as of Oct 21, 2026
  • MCK gained 13.9% over the past month versus 0.0% for the S&P 500, ranking 24th of 497 S&P 500 stocks.
  • Over 12 months it returned +29.1%, 13.3 points ahead of the S&P 500, and trades 1.4% below its 52-week high.
  • In the last 30 days 2 analysts raised earnings estimates and 0 cut; forward EPS moved +0.1% (+0.6% over 90 days).
  • It sits in the Drug distribution segment of the Healthcare Value Chain, where the 1-month median return is +13.9%.
  • The daily chart reads Intermediate uptrend · Upside breakout (since Oct 14, 2026).
Market cap$118.4B
12-month return+29.1%
Forward P/E20.1×
Mean target vs price−3.6%

One-year price with 50- and 200-day averages

Open in Hub
7118089051002JanAprJulOct
1015.5050-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

MCK+13.9%
Sector median−8.7%
S&P 5000.0%
MCK+23.2%
Sector median−5.4%
S&P 500+4.7%
MCK+22.5%
Sector median−1.5%
S&P 500+8.7%
MCK+29.1%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the S&P 50024 / 497
3-month rank in its sector · Healthcare125 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Intermediate uptrend · Upside breakoutConfirmed

Holding since Oct 14, 2026

  • Close above EMA20 above EMA50
  • EMA50 rose over the last ten sessions
  • Confirmed swing highs and lows are rising
This pattern on this stock

64 occurrences in 10 years. The median move over the next 20 sessions was +1.6%, positive 58% of the time, against +1.7% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$50.63
30-day change+0.1%
90-day change+0.6%
Mean target$979.36 −3.6%
Raised (30d) 2Cut (30d) 0

14 analysts cover the stock

Where it sits in the supply chain

Healthcare Value Chain · Distribution & PBMs

Explore the full chain map in Hub
Supplied by
Obesity & metabolic (GLP-1)+3.8%
LLY+8.6%1 monthNVO−0.9%1 month
Large pharma−0.7%
JNJ−4.2%1 monthMRK−0.7%1 monthABBV+7.4%1 monthPFE+6.9%1 monthBMY−0.8%1 month
Biotech+0.4%
AMGN+6.8%1 monthREGN+0.2%1 monthGILD+0.6%1 monthVRTX+1.9%1 monthALNY−10.6%1 monthMRNA+34.6%1 monthBIIB+6.9%1 monthINSM−22.2%1 monthINCY−10.6%1 monthCATX−22.3%1 month
Generics & established medicines+7.4%
VTRS+7.4%1 month
Its segment
Drug distribution+13.9%
MCK+13.9%1 monthCOR+8.3%1 monthCAH+16.2%1 month

Three distributors handle most US prescription drug flow; revenue grows with prescription volume and high-priced specialty drugs, including GLP-1s.

Sells into
PBMs & pharmacies+9.3%
CVS+7.3%1 monthCI+11.2%1 monthUNH+11.8%1 month6618.HK+7.3%1 month
Hospitals & care delivery+8.4%
HCA+4.9%1 monthUNH+11.8%1 month

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−27.2%
Volatility, 60D29.3%
From 52-week high−1.4%
From 52-week low+40.0%
Trailing P/E27.2×
Forward P/E20.1×
CORCencora, Inc.CAHCardinal Health, Inc.LLYEli LillyJNJJohnson & JohnsonMRKMerckABBVAbbViePFEPfizerBMYBristol Myers Squibb

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗